Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of “Moderate Buy” by Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $6.8750.

A number of research firms have commented on SRTS. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st. Maxim Group dropped their price objective on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Finally, Alliance Global Partners started coverage on shares of Sensus Healthcare in a research note on Friday, March 6th. They set a “buy” rating and a $7.50 price target on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Opes Wealth Management LLC acquired a new position in shares of Sensus Healthcare during the third quarter worth about $50,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the fourth quarter worth about $77,000. Jane Street Group LLC acquired a new position in shares of Sensus Healthcare during the fourth quarter worth about $79,000. Mindset Wealth Management LLC increased its stake in shares of Sensus Healthcare by 28.1% during the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after acquiring an additional 11,000 shares during the period. Finally, Ingalls & Snyder LLC acquired a new position in shares of Sensus Healthcare during the fourth quarter worth about $219,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Price Performance

Shares of SRTS opened at $3.61 on Friday. Sensus Healthcare has a 1-year low of $2.82 and a 1-year high of $5.92. The stock has a market cap of $59.42 million, a PE ratio of -7.68 and a beta of 1.19. The firm has a fifty day moving average price of $4.04 and a 200 day moving average price of $4.16.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The business had revenue of $3.39 million during the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.